医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
14期
41-41,42
,共2页
米非司酮%米索前列醇%人工流产
米非司酮%米索前列醇%人工流產
미비사동%미색전렬순%인공유산
Mifepristone%Misoprostol%Abortion
目的：探讨米非司酮联合米索前列醇终止16～24周妊娠的疗效和安全性。方法：将我院收治的孕龄16～24周要求终止妊娠的孕妇50例作为研究对象进行回顾性分析，其中口服给药患者23例，阴道给药患者27例。比较两组患者的总有效率、引产时间、产后出血量、阴道出血时间及米索前列醇使用剂量等有无差别。结果：口服给药组完全流产15例，不全流产7例，无效1例，清宫率为64%，总有效率为96%；阴道给药组完全流产17例，不全流产10例，无效0例，清宫率为56%，总有效率为100%，两组清宫率、总有效率比较差异无统计学意义（P>0.05）。阴道给药组患者引产时间（P<0.05）、产后出血量（P<0.05）及米索前列醇用量（P<0.05）均小于口服给药组，而两种患者阴道出血时间无明显差别（P>0.05）。两组患者不良反应发生率差别无统计学意义（P<0.05）。结论：米非司酮联合米索前列醇终止16～24周妊娠临床疗效确切，安全有效。经阴道给药效果更好。
目的：探討米非司酮聯閤米索前列醇終止16～24週妊娠的療效和安全性。方法：將我院收治的孕齡16～24週要求終止妊娠的孕婦50例作為研究對象進行迴顧性分析，其中口服給藥患者23例，陰道給藥患者27例。比較兩組患者的總有效率、引產時間、產後齣血量、陰道齣血時間及米索前列醇使用劑量等有無差彆。結果：口服給藥組完全流產15例，不全流產7例，無效1例，清宮率為64%，總有效率為96%；陰道給藥組完全流產17例，不全流產10例，無效0例，清宮率為56%，總有效率為100%，兩組清宮率、總有效率比較差異無統計學意義（P>0.05）。陰道給藥組患者引產時間（P<0.05）、產後齣血量（P<0.05）及米索前列醇用量（P<0.05）均小于口服給藥組，而兩種患者陰道齣血時間無明顯差彆（P>0.05）。兩組患者不良反應髮生率差彆無統計學意義（P<0.05）。結論：米非司酮聯閤米索前列醇終止16～24週妊娠臨床療效確切，安全有效。經陰道給藥效果更好。
목적：탐토미비사동연합미색전렬순종지16～24주임신적료효화안전성。방법：장아원수치적잉령16～24주요구종지임신적잉부50례작위연구대상진행회고성분석，기중구복급약환자23례，음도급약환자27례。비교량조환자적총유효솔、인산시간、산후출혈량、음도출혈시간급미색전렬순사용제량등유무차별。결과：구복급약조완전유산15례，불전유산7례，무효1례，청궁솔위64%，총유효솔위96%；음도급약조완전유산17례，불전유산10례，무효0례，청궁솔위56%，총유효솔위100%，량조청궁솔、총유효솔비교차이무통계학의의（P>0.05）。음도급약조환자인산시간（P<0.05）、산후출혈량（P<0.05）급미색전렬순용량（P<0.05）균소우구복급약조，이량충환자음도출혈시간무명현차별（P>0.05）。량조환자불량반응발생솔차별무통계학의의（P<0.05）。결론：미비사동연합미색전렬순종지16～24주임신림상료효학절，안전유효。경음도급약효과경호。
Objective To assess the clinical efficacy and side effects of mifepristone combined with misoprostol in the treatment of 16-24 weeks of gestation.Methods 50 subjects with 16-24 weeks of gestation were reviewed and retrospectively analyzed in our hospital. 23 patients were given the misoprostol orally and other 27 cases were given misoprostol intravaginally. The total efficacy rate, the duration of labor induction, the blood loss, the period of vagina hemorrhage and dosage of misoprostol were analyzed and compared between the two groups.Results In the oral group, 15 cases were complete abortion, 7 subjects were incomplete abortion and 1 cases was invalidation, with an vacuum aspiration rate and total efficacy rate of 65% and 96% respectively. In the intravaginally group, 17 cases were complete abortion, were incomplete abortion and 0 were invalidation with an vacuum aspiration rate and total efficacy rate of 56% and 100% respectively. There was no statically difference of vacuum aspiration rate and total efficacy rate between the two groups(P>0.05). The side effects between the two groups were not statistically different (P<0.05).ConclusionMifepristone and misoprostol could be effective and safe in the treatment of terminate pregnancies of 16-24 weeks, but administration in intravaginally was better than that of orally.
